#161803

KPAR1.3 Cell Line

Cat. #161803

KPAR1.3 Cell Line

Cat. #: 161803

Availability: 8-10 weeks

Organism: Mouse

Tissue: Lung

Model: Mutant

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Julian Downward, Jesse Boumelha, Sophie de Carne

Institute: The Francis-Crick Institute

Primary Citation: Boumelha et al. 2022. Cancer Research. 82(19):3435-3448. PMID: 35930804.

Tool Details
Handling
Related Tools
References
Documentation

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: KPAR1.3 Cell Line
  • Alternate name:  
  • Cancer: Lung cancer
  • Research fields: Cancer
  • Organism: Mouse
  • Tissue: Lung
  • Donor:  
  • Growth properties: Adherent
  • Model: Mutant
  • Model description: Single cell clone from a cell line isolated from KrasLSL-G12D/+; Trp53fl/fl; Rosa26A3Bi;Rag1-/- mouse (KPAR) lung tumours
  • Crispr: No
  • Products or characteristics of interest:  
  • Description: KPAR1.3 cells (also called KPAR) are a single cell clone derived from a cell line isolated from a lung tumor of KRASLSL-G12D/+; Trp53fl/fl; Rosa26A3Bi; Rag1-/- mice. Although cell line is derived from a heterozygous KRAS-G12D/WT model, the cell line is homozygous for the mutation. Mouse models of mutant KRAS-driven lung cancer with an elevated tumour mutational burden by expressing the human DNA cytosine deaminase, APOBEC3B, to mimic the mutational signature seen in human lung cancer. The ability of KRAS/KRASG12 inhibitors to cause regression of KRASG12C expressing tumours was markedly potentiated by the adaptive immune system.
  • Production details: Single cell clone from a cell line isolated from KrasLSL-G12D/+; Trp53fl/fl; Rosa26A3Bi;Rag1-/- mouse (KPAR) lung tumours
  • Biosafety level: 1
  • Recommended controls:  

Handling

  • Passage number:  
  • Growth medium: DMEM supplemented with 10% FCS, 4 mM l-glutamine, penicillin (100 U/ml), and streptomycin (100 mg/ml)
  • Temperature:  37°C
  • Atmosphere:  5% CO2
  • Shipping conditions: Dry ice
  • Storage medium:  
  • Storage conditions: Liquid Nitrogen
  • Subculture routine: These cells are especially sensitive to centrifugation immediately post-thaw. We recommend adding the thawed culture to 4 mL of prewarmed recommended medium in a T-25 culture flask and changing the medium after the cells have attached either later in the day or the next morning. Significant cell death is expected at this point. Once the cells have revived, they can be centrifuged and sub cultured. Split 1:12 – 1:15 twice a week. Please also see detailed protocol within the Product Datasheet in the Documentation section below.
  • Cultured in antibiotics: Penicillin, Streptomycin
  • Str profiling:  

Related Tools

  • Related tools:  

References

  • Boumelha et al. 2024. Cancer Research. 84(14):2231–2246. PMID: 38635884
  • Boumelha et al. 2022. Cancer Research. 82(19):3435-3448. PMID: 35930804.

Documentation